Please wait, while we are loading the content...
Please wait, while we are loading the content...
Content Provider | World Health Organization (WHO)-Global Index Medicus |
---|---|
Author | Nakagawa, Hidemi Niiro, Hiroaki Ootaki, Kenji |
Spatial Coverage | Japan |
Description | Author Affiliation: Nakagawa H ( Department of Dermatology, The Jikei University, School of Medicine, 3-25-8 Nishishinbashi, Minato-ku, Tokyo 105-8461, Japan. Electronic address: hidemi@jikei.ac.jp.); Niiro H ( Department of Medicine and Biosystemic Science, Faculty of Medicine, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka-shi, Fukuoka 812-8582, Japan. Electronic address: hniiro@med.kyushu-u.ac.jp.); Ootaki K ( Kyowa Hakko Kirin Co., Ltd., Tokyo, Japan. Electronic address: kenji.ootaki@kyowa-kirin.co.jp.) |
Abstract | BACKGROUND: Brodalumab (KHK4827 or AMG 827) is a human monoclonal antibody that binds to the human interleukin (IL)-17 receptor A and blocks the biological activities of IL-17A, IL-17F, IL-17A/F, and IL-17E also known as IL-25. A 12-week phase 2 trial in the USA, Europe, and other countries showed the good efficacy of brodalumab in treating patients with moderate to severe plaque psoriasis. However, with the exception of a phase 1 study, a clinical trial of brodalumab in psoriasis has not been undertaken in Japan. OBJECTIVE: To evaluate the efficacy and safety of brodalumab in Japanese patients with moderate-to-severe plaque psoriasis, including psoriatic arthritis, in a multicenter, randomized, double-blind, placebo-controlled, parallel-group comparative phase 2 study, and to assess the pharmacokinetics of brodalumab. METHODS: Japanese patients with moderate-to-severe plaque psoriasis, including psoriatic arthritis, were randomized to receive 70mg, 140mg, or 210mg of brodalumab, or placebo, injected subcutaneously at baseline and weeks 1, 2, 4, 6, 8, and 10. The primary efficacy endpoint was the percentage improvement in the Psoriasis Area and Severity Index (PASI) score from baseline to week 12. Secondary efficacy endpoints included the percentage of patients with ≥75% reduction of PASI scores (PASI 75), ≥90% (PASI 90), and 100% (PASI 100) and the percentage of patients with a static physician's global assessment (sPGA) of 0 (clear) or 1 (almost clear) at week 12. Safety was evaluated by assessing the adverse events (AE) and the patients' hematologic and laboratory values. RESULTS: At week 12, the mean percentage improvements in the PASI scores were 37.7%, 82.2%, 96.8%, and 9.4% in the 70mg, 140mg, 210mg, and placebo groups, respectively, (p<0.001 for all comparisons with placebo). The percentage of patients with PASI 75, PASI 90, and PASI 100 at week 12 were 7.9%, 2.6%, and 0%, respectively, in the placebo group, 25.6%, 15.4%, and 2.6%, respectively, in the 70mg brodalumab group, 78.4%, 64.9%, and 35.1%, respectively, in the 140mg brodalumab group, and 94.6%, 91.9%, and 59.5%, respectively, in the 210mg brodalumab group. Concerning psoriatic arthritis, at week 12, the numbers (%) of patients fulfilling the American College of Rheumatology response criteria for a 20% improvement were 0 (0%) in the placebo group, and 1 (20%), 2 (40%), and 4 (100%) in the 70mg, 140mg, and 210mg brodalumab groups, respectively. The percentages of patients with Dermatology Life Quality Index scores of 0 or 1 at week 12 were greater in the 140mg (54.1%) and the 210mg (56.8%) brodalumab groups than in the placebo group (8.8%). The most common AE in the brodalumab groups were nasopharyngitis (12.4% vs. 7.9% for placebo), diarrhea (5.3% vs. 0%), upper respiratory tract inflammation (3.5% vs. 0%), and folliculitis (3.5% vs. 0%). CONCLUSION: The rapid, robust efficacy of brodalumab and its favorable safety profile shown in the current study confirm previous studies conducted in Caucasian people, further warranting the use of brodalumab as a new treatment option for plaque psoriasis. |
File Format | HTM / HTML |
ISSN | 09231811 |
Issue Number | 1 |
Volume Number | 81 |
e-ISSN | 1873569X |
Journal | Journal of Dermatological Science |
Language | English |
Publisher | Elsevier |
Publisher Date | 2016-01-01 |
Publisher Place | Netherlands |
Access Restriction | Subscribed |
Subject Keyword | Discipline Dermatology Antibodies, Monoclonal Therapeutic Use Arthritis, Psoriatic Therapy Psoriasis Receptors, Interleukin-17 Antagonists & Inhibitors Adult Aged Adverse Effects Blood Immunology Pathology Asian Continental Ancestry Group Double-blind Method Female Humans Japan Male Middle Aged Severity Of Illness Index Treatment Outcome Young Adult Clinical Trial, Phase Ii Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-u.s. Gov't |
Content Type | Text |
Resource Type | Article |
Subject Domain (in MeSH) | Eukaryota Musculoskeletal Diseases Skin and Connective Tissue Diseases Amino Acids, Peptides, and Proteins Diagnosis Investigative Techniques Persons Geographic Locations |
Subject | Molecular Biology Dermatology Biochemistry |
National Digital Library of India (NDLI) is a virtual repository of learning resources which is not just a repository with search/browse facilities but provides a host of services for the learner community. It is sponsored and mentored by Ministry of Education, Government of India, through its National Mission on Education through Information and Communication Technology (NMEICT). Filtered and federated searching is employed to facilitate focused searching so that learners can find the right resource with least effort and in minimum time. NDLI provides user group-specific services such as Examination Preparatory for School and College students and job aspirants. Services for Researchers and general learners are also provided. NDLI is designed to hold content of any language and provides interface support for 10 most widely used Indian languages. It is built to provide support for all academic levels including researchers and life-long learners, all disciplines, all popular forms of access devices and differently-abled learners. It is designed to enable people to learn and prepare from best practices from all over the world and to facilitate researchers to perform inter-linked exploration from multiple sources. It is developed, operated and maintained from Indian Institute of Technology Kharagpur.
Learn more about this project from here.
NDLI is a conglomeration of freely available or institutionally contributed or donated or publisher managed contents. Almost all these contents are hosted and accessed from respective sources. The responsibility for authenticity, relevance, completeness, accuracy, reliability and suitability of these contents rests with the respective organization and NDLI has no responsibility or liability for these. Every effort is made to keep the NDLI portal up and running smoothly unless there are some unavoidable technical issues.
Ministry of Education, through its National Mission on Education through Information and Communication Technology (NMEICT), has sponsored and funded the National Digital Library of India (NDLI) project.
Sl. | Authority | Responsibilities | Communication Details |
---|---|---|---|
1 | Ministry of Education (GoI), Department of Higher Education |
Sanctioning Authority | https://www.education.gov.in/ict-initiatives |
2 | Indian Institute of Technology Kharagpur | Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project | https://www.iitkgp.ac.in |
3 | National Digital Library of India Office, Indian Institute of Technology Kharagpur | The administrative and infrastructural headquarters of the project | Dr. B. Sutradhar bsutra@ndl.gov.in |
4 | Project PI / Joint PI | Principal Investigator and Joint Principal Investigators of the project |
Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon |
5 | Website/Portal (Helpdesk) | Queries regarding NDLI and its services | support@ndl.gov.in |
6 | Contents and Copyright Issues | Queries related to content curation and copyright issues | content@ndl.gov.in |
7 | National Digital Libarray of India Club (NDLI Club) | Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach | clubsupport@ndl.gov.in |
8 | Digital Preservation Centre (DPC) | Assistance with digitizing and archiving copyright-free printed books | dpc@ndl.gov.in |
9 | IDR Setup or Support | Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops | idr@ndl.gov.in |
Loading...
|